Telix Pharmaceuticals Stock

Telix Pharmaceuticals Current Liabilities

Delisted·Jun 19, 2026

The Current Liabilities of Telix Pharmaceuticals (TLX.AX) as of Aug 23, 2026 is 231.62 M USD. In the previous year, Current Liabilities was 205.09 M USD — a change of 12.94% (higher).

Current Liabilities

231.62 MUSD

YoY

12.94%

Last updated:

Current Liabilities of Telix Pharmaceuticals is 2026 231.62 M USD. Current Liabilities of Telix Pharmaceuticals was 2025 205.09 M USD. It decreases by 12.94% higher compared to the previous year.

The Telix Pharmaceuticals Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
8.24 M USD
Jan 1, 2019
10.63 M USD
Jan 1, 2020
19.96 M USD
Jan 1, 2021
37.98 M USD
Jan 1, 2022
55.48 M USD
Jan 1, 2023
132.67 M USD
Jan 1, 2024
205.09 M USD
Jan 1, 2025
231.62 M USD
The Telix Pharmaceuticals Current Liabilities history
YEARCurrent LiabilitiesYoY
231.62 MUSD+12.94%
205.09 MUSD+54.59%
132.67 MUSD+139.11%
55.48 MUSD+46.08%
37.98 MUSD+90.33%
19.96 MUSD+87.82%
10.63 MUSD+28.92%
8.24 MUSD+461.27%
1.47 MUSD
Access this data via the Eulerpool API

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Current Liabilities of Telix Pharmaceuticals is 231.62 M USD in 2026.

Current Liabilities of Telix Pharmaceuticals changed from 205.09 M USD to 231.62 M USD, representing a 12.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Telix Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals